Matthew G Fury

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 9:681-9. 2011
  2. ncbi A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 118:5008-14. 2012
  3. ncbi A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USA
    Cancer Chemother Pharmacol 70:121-8. 2012
  4. ncbi A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Matthew G Fury
    Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 69:591-8. 2012
  5. ncbi A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:795-801. 2011
  6. ncbi Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 33:1340-5. 2011
  7. ncbi Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
  8. ncbi Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes
    Benjamin H Lok
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1851-7. 2012
  9. ncbi Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
  10. ncbi Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anticancer Res 31:249-53. 2011

Detail Information

Publications24

  1. ncbi Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 9:681-9. 2011
    ..Avenues for ongoing research are also presented...
  2. ncbi A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 118:5008-14. 2012
    ..HNSCC tumors that express high levels of vascular endothelial growth factor have been associated with a worse prognosis, and bevacizumab may sensitize tumors to cisplatin and radiation...
  3. ncbi A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USA
    Cancer Chemother Pharmacol 70:121-8. 2012
    ..The mammalian target of rapamycin complex 1 (mTORC1) is aberrantly activated in many head and neck squamous cell carcinomas (HNSCCs). This phase I study combines the mTORC1 inhibitor temsirolimus with carboplatin and paclitaxel...
  4. ncbi A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Matthew G Fury
    Department of Medicine, Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 69:591-8. 2012
    ..We conducted a phase I study to establish the recommended phase II of oral everolimus to be given with low-dose weekly intravenous cisplatin...
  5. ncbi A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:795-801. 2011
    ..A phase 1 study of pemetrexed plus gemcitabine given every 2 weeks demonstrated encouraging preliminary efficacy against head and neck squamous cell cancer (HNSCC)...
  6. ncbi Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 33:1340-5. 2011
    ..The purpose of this study is to determine if p16 immunoreactivity is associated with aberrant expression of components of the PI3 kinase pathway...
  7. ncbi Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
    ..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment...
  8. ncbi Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes
    Benjamin H Lok
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1851-7. 2012
    ..To analyze the effect of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) on treatment outcomes in patients treated with definitive intensity-modulated radiation therapy (IMRT) for oropharyngeal cancer (OPC)...
  9. ncbi Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
    ..The goal of this study was to assess the prognostic value of pretreatment DCE-MRI in head and neck squamous cell carcinoma (HNSCC) patients with nodal disease undergoing chemoradiation therapy or surgery...
  10. ncbi Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anticancer Res 31:249-53. 2011
    ..Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC)...
  11. ncbi Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination
    Anuradha Thiagarajan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 83:220-7. 2012
    ..This study aims to evaluate contributions of magnetic resonance imaging (MRI), positron emission tomography (PET), and physical examination (PE) to GTV delineation in oropharyngeal cancer (OPC)...
  12. ncbi Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma
    Eric J Sherman
    1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Thyroid 23:593-9. 2013
    ..7 (0.46-12) months, respectively. Conclusions: We observed preliminary signs of in vivo reversal of RAI resistance after treatment with romidepsin. However, no major responses were observed and accrual was poor after the grade 5 AE...
  13. ncbi A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC and Weill Cornell Medical College, New York, NewYork
    Cancer 119:1823-31. 2013
    ..The authors conducted a phase 1 study to evaluate the addition of oral everolimus to cisplatin and docetaxel as induction chemotherapy for head and neck cancer...
  14. ncbi Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 82:291-8. 2012
    ..To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC)...
  15. ncbi A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Compr Canc Netw 10:1391-8. 2012
    ..Cetuximab, 500 mg/m(2), q2w achieves similar efficacy as conventional dosing for patients with recurrent or metastatic HNSCC. Escalating the dose to 750 mg/m(2) q2w offers no obvious therapeutic advantage...
  16. ncbi Molecular-targeted therapies in head and neck cancer
    Shyam D Rao
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Radiat Oncol 22:207-13. 2012
    ..In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation...
  17. ncbi Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1403-10. 2010
    ....
  18. ncbi A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..Vitamin B(12) and folate supplementation may allow for further dose escalation of pralatrexate and probenecid. This is a suitable question for a future study...
  19. ncbi A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 57:155-63. 2008
    ..Preclinical data suggest that co-administration of granulocyte-colony stimulating factor (G-CSF) may enhance the tumor cytotoxicity of bispecific antibodies...
  20. ncbi A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  21. ncbi Induction chemotherapy in the management of head and neck cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Oncol 101:292-8. 2010
    ....
  22. ncbi Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
    Radiother Oncol 101:425-30. 2011
    ..We evaluated our more recent experience with this approach, which included pathologic confirmation of all cases...
  23. ncbi A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 25:165-72. 2007
    ..This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers...
  24. ncbi A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy
    Matthew G Fury
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA
    Cancer J 11:241-7. 2005
    ..8 months for sites below the clavicle. DISCUSSION: Angiosarcoma is an aggressive malignancy characterized by biologic heterogeneity at different anatomic sites and relative sensitivity to paclitaxel and doxorubicin...